This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignees: National Institutes of Biomedical Innovation, Health and Nutrition, Other. Active years: 2021-2025.
Company Filing History:
1 out of 23 
1 out of 834,411 Years Active: 2021-2025
Title: Burcu Temizoz: Innovator in Immunology
Introduction
Burcu Temizoz is a prominent inventor based in Suita, Japan. She has made significant contributions to the field of immunology, particularly in the development of novel adjuvants for enhancing immune responses. With a total of 2 patents, her work focuses on advancing techniques for anti-cancer and anti-allergic therapies.
Latest Patents
Temizoz's latest patents include a Th1-inducing adjuvant comprising a combination of different nucleic acid adjuvants. This invention aims to induce a novel Th1 response, promoting the activation of cytotoxic T cells and enhancing anti-cancer and anti-allergic activities. The patent details a combination of a CpG oligonucleotide and an STING agonist, which can be used as a type-I adjuvant. Additionally, it describes an anti-cancer agent that combines a CpG oligonucleotide with an STING agonist, as well as a composition designed to reduce or eliminate the IgE-inducing activity of an STING agonist.
Career Highlights
Throughout her career, Burcu Temizoz has worked with esteemed organizations, including the National Institutes of Biomedical Innovation, Health and Nutrition. Her research has significantly impacted the development of immunotherapeutic strategies.
Collaborations
Temizoz has collaborated with notable colleagues, including Ken Ishii and Etsushi Kuroda, contributing to the advancement of her research and innovations in the field.
Conclusion
Burcu Temizoz is a trailblazer in immunology, with her innovative patents paving the way for new therapeutic approaches. Her work continues to inspire advancements in the fight against cancer and allergies.